Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Frindel

Showing results (101-110 of 104) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 104 results.
Experimental Hematology|September 1, 1987
Stimulatory effects of plasma from patients with acute nonlymphoblastic leukemia on early erythroid progenitors and pluripotent stem cellsL Kobari, N Dainiak, A Najman, et al.
Annals of the New York Academy of Sciences|January 1, 1991
Amelioration of chemotherapy-induced toxicity by cotreatment with AcSDKP, a tetrapeptide inhibitor of hematopoietic stem cell proliferationA E Bogden, P Carde, E D de Paillette, et al.
British Journal of Haematology|April 1, 1995
AcSDKP serum concentrations vary during chemotherapy in patients with acute myeloid leukaemiaE Liozon, L Volkov, L Comte, et al.
International Journal of Cancer|April 9, 1998
Goralatide (AcSDKP), a negative growth regulator, protects the stem cell compartment during chemotherapy, enhancing the myelopoietic response to GM-CSFA E Bogden, J P Moreau, C Gamba-Vitalo, et al.
Pageof 11

Showing results (101-110 of 104) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 104 results.
Experimental Hematology|September 1, 1987
Stimulatory effects of plasma from patients with acute nonlymphoblastic leukemia on early erythroid progenitors and pluripotent stem cellsL Kobari, N Dainiak, A Najman, et al.
Annals of the New York Academy of Sciences|January 1, 1991
Amelioration of chemotherapy-induced toxicity by cotreatment with AcSDKP, a tetrapeptide inhibitor of hematopoietic stem cell proliferationA E Bogden, P Carde, E D de Paillette, et al.
British Journal of Haematology|April 1, 1995
AcSDKP serum concentrations vary during chemotherapy in patients with acute myeloid leukaemiaE Liozon, L Volkov, L Comte, et al.
International Journal of Cancer|April 9, 1998
Goralatide (AcSDKP), a negative growth regulator, protects the stem cell compartment during chemotherapy, enhancing the myelopoietic response to GM-CSFA E Bogden, J P Moreau, C Gamba-Vitalo, et al.
Pageof 11